drugset / Trial / NCT04770610
Study of OT-101 in Treating Myopia
Phase 3
Active not recruiting
678 enrolled
Ocumension (Hong Kong) Limited
ORA, Inc. · collabStatistics & Data Corporation · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter safety, tolerability, and efficacy study of atropine sulfate 0.01% (OT-101) as an investigational treatment for myopia in pediatric subjects
Timeline
- Start
- 2021-04-01
- Primary completion
- 2027-03
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atropine | Other / unclassified | 0.01 % | — |